¸»±âÀÇ·áÀÇ °æÁ¦Àû ¿ä¼Ò¿¡ °üÇÑ ³íÀÇ : ¹Ì±¹ ¸ÞµðÄÉ¾î »óȲÀ» Áß½ÉÀ¸·Î
Health Economic Approach to End-of-Life Care in the US : Based on Medicare

ÀÇ·á¹ýÇÐ 2014³â 15±Ç 1È£ p.335 ~ p.373

(Suk Ryan) - University of Utah Graduate School Department of Economics

Abstract

ÇÑ ÀÚ·á¿¡ ÀÇÇϸé 2011³â ¹Ì±¹ÀÇ ÀÇ·áºñ ÁöÃâ ÃѾ×Àº ±¹³»ÃÑ»ý»êÀÇ ¾à 18 ÆÛ¼¾Æ®¿¡ ´ÞÇÏ¿´À¸¸ç, ±× ºñÀ²Àº ´Ù¸¥ ´ë´Ù¼ö ¼±Áø±¹ÀÇ µÎ ¹è¿¡ ÇØ´çÇÏ´Â °ÍÀ̾ú´Ù. ±×Áß ¸ÞµðÄÉ¾î ºñ¿ëÀº Àüü ÀÇ·áºñÀÇ 21 ÆÛ¼¾Æ®ÀÎ 5540¾ï ´Þ·¯ ¿´´Â µ¥, ȯÀÚÀÇ ÃÖÈÄ 6 °³¿ù¿¡ µé¾î°£ ÀÇ·áºñ´Â ±× 5540¾ï ´Þ·¯ÀÇ 28 ÆÛ¼¾Æ® (Àüü ÀÇ·áºñÀÇ 5.9 ÆÛ¼¾Æ®)ÀÎ 1700¾ï ´Þ ·¯¿¡ ´ÞÇÏ¿´´Ù. ÀÌ·¯ÇÑ ¸»±âÀÇ·áÀÇ °íºñ¿ë¼ºÀº ¾î¶² »çÀ¯¿¡ ±âÀÎÇϸç, ±× ÇØ¼Ò ¹æ¾ÈÀº ¹«¾ùÀΰ¡. Áö³­ ¼ö½Ê ³â °£ÀÇ ÀÇ·á°æÁ¦ÇÐÀû ¿¬±¸´Â ¸»±âÀÇ·á°¡ ÀϹÝÀûÀ¸·Î °ø±Þ¹Î°¨¼ºÀ» Áö´Ï¸ç ºñ¿ë´ëºñ È¿À²¼ºÀÌ ¸Å¿ì ³·´Ù´Â °á·Ð¿¡ µµ´ÞÇÏ¿´´Ù. ÀÇ·á¼­ ºñ½º °ø±ÞÀÇ ¾çÀº Áúº´ÀÇ Á¤µµ³ª ȯÀÚÀÇ ¼±È£µµ¿Í´Â ¹«°üÇϰí, ±×º¸´Ù´Â ÀÇ·á¼­ºñ½º °ø±ÞÀÚ¿ø¿¡ ¹Î°¨ÇÏ°Ô ¹ÝÀÀÇÑ ´Ù´Â °ÍÀÌ´Ù. ÀÌ´Â ¸»±âÀÇ·á¿¡¼­´Â ÀÇ·áÀÚ¿øÀÌ °ú¿ëµÈ´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. ÇÑÆí "´õ ¸¹Àº ÀÇ·áóġ¿¡ ´õ ³ªÀº È¿¿ë"À̶ó´Â ÀϹÝÀûÀÎ Ã߷аú´Â ¹Ý´ë·Î, ¸¹Àº ÀÇ·áóġÀÇ °á°ú´Â ¿ÀÈ÷·Á ¸Å¿ì ºÎÁ¤ÀûÀÎ °ÍÀ̾ú´Ù. ½ÇÁ¦ ȯÀÚµéÀÇ ¼±È£¿Í °ü½É»ç´Â °Ý·ÄÇÑ ¸»±âÀÇ·á°¡ ±âµµÇÏ´Â °Í°ú´Â ¾ÆÁÖ ´Þ¶ú´ø °ÍÀÌ´Ù. ÀÌ ³í¹®Àº ¸ÕÀú ¸»±âÀÇ·á¿¡¼­ÀÇ °ø±Þ¹Î°¨¼ºÀÇ ¿øÀÎÀ» ºÐ¼®ÇÑ´Ù. ±× ¿øÀÎÀ¸·Î´Â °Ý·ÄÇÑ Ä¡·á¿Í ±× È¿¿ë¼º¿¡ ´ëÇÑ ÀϹÝÀûÀÎ ¿ÀÇØ, ÀÇ»çµéÀÇ È¯ÀÚ¿¡ ´ëÇÑ Á÷¾÷ÀûÀÎ »ç¸íÀǽÄ, ȯÀÚ ÀÚ½ÅÀÇ ¸»±âÀÇ·á ÀÇÇâ°áÁ¤ÀÇ ºÎÀç, ÀÇ»çµéÀÇ ¹ýÀû Ã¥ÀÓ¿¡ ´ëÇÑ ¿ì·Á, ÀÇ·á±â°üÀÇ °æ¿µÂ÷¿ø¿¡¼­ÀÇ °ü¸®Àü·« µîÀ» µé ¼ö ÀÖ´Ù. ´ÙÀ½À¸·Î, ³í¹®¿¡¼­´Â ¸»±âÀÇ·áÀÇ °ø±Þ¹Î°¨¼º¿¡¼­ ¿¬À¯ÇÏ´Â °úÀ×Áø·á¿¡ ´ëÇÑ Çö½ÇÀû ÇØ°áÃ¥À» Á¦½ÃÇÑ´Ù. ±× ÇØ°á Ã¥Àº µÎ °¡Áö Ãø¸éÀ¸·Î ³ª´©¾î¼­ µé ¼ö Àִµ¥, Çϳª´Â »çÀüÀÇ·áÀÇÇâ¼­ Á¦µµÀÇ È°¼ºÈ­ ¹æ¾ÈÀ̰í, ´Ù¸¥ Çϳª´Â ÀÇ ·á±â°ü °æ¿µ°ü¸®Àü·«Àû °üÁ¡¿¡¼­ÀÇ ¹æ¾ÈÀÌ´Ù. ¿ì¼± »çÀüÀÇ·áÀÇÇâ¼­ÀÇ È°¿ëµµ¸¦ Á¦°íÇϱâ À§Çؼ­ ´ÙÀ½°ú °°Àº ±¸Ã¼Àû ³ë·ÂÀÌ ÇÊ¿äÇÏ´Ù. Áï ÀÇ»çµéÀÇ ¸»±âÀÇ·á¿¡ ´ëÇÑ Åµµ¸¦ ¹Ù²Ùµµ·Ï ÇÏ´Â »õ·Î¿î ÀÇ·áÀ±¸® ±³À° ½Ç½Ã, ÀÇ»ç¿Í ȯÀÚ °£ ¸»±âÀÇ·á¿¡ ´ëÇÑ ¼ÒÅë ±âȸÀÇ °­È­, ȯÀÚ ¿Í ¸»±âÀÇ·á¿¡ ´ëÇÑ ´ëÈ­¸¦ Àû±ØÀûÀ¸·Î ½ÇõÇÏ´Â Àǻ翡 ´ëÇÑ º¸»óÁ¦µµ µµÀÔ, ÀÏ¹Ý °ø°ø¿¡ ´ëÇÑ °ü·Ã ±³À° È®´ë, ¿Â¶óÀÎ µî·Ï½Ã½ºÅÛ°ú °°Àº ¿ëÀÌÇÏ°íµµ °ø½ÄÀûÀÎ »çÀüÀÇ·áÀÇÇâ¼­ µî·ÏüÁ¦ÀÇ ±¸Ãà È®´ë µîÀÌ ÇÊ¿äÇÏ´Ù. °æ¿µ°ü¸®Àû Ãø¸é¿¡¼­´Â ´ëü Àü·«ÀÌ ÇÊ¿äÇÏ´Ù. ¿¹ÄÁ´ë ºÒÇÊ¿äÇÑ ºñ¿ëÀ» Àý°¨Çϰí ÀÇ·á°ø±ÞÀڷμ­ÀÇ °¡Ä¡¸¦ ÀçÁ¤ ¸³ÇÏ´Â µîÀÇ »õ·Î¿î À繫Àü·«°ú °æ¿µ±³À°°èȹ µîÀÌ °í·ÁµÇ¾î¾ß ÇÒ °ÍÀÌ´Ù. È¿°úÀûÀ¸·Î ¸»±âÀÇ·áÀÇ °æÁ¦Àû ¹®Á¦Á¡À» ÇØ¼ÒÇϰí ȯÀÚ¿¡°Ô ´õ ³ªÀº ÀÇ·á°æÇèÀ» Á¦°øÇϱâ À§Çؼ­´Â ÀǷᡤȯÀÚ¡¤±¹ °¡ µî ¸ðµç ºÎ¹®¿¡¼­ °üÇà°ú ¿ÀÇØ¿¡¼­ ºñ·ÔµÈ ½ÅÁ¶°¡ ½Ã±ÞÈ÷ ¼öÁ¤µÇ¾î¾ß Çϰí, ±× ±âÃÊ À§¿¡¼­ Á¦µµ¿Í ¹®È­°¡ °³ ¼±µÇ¾î¾ß ÇÏ´Â °ÍÀÌ´Ù.
According to one Medicare report, in the US, total federal spending on health care expends almost 18 percent of the nation¡¯s GDP, about double what most industrialized nations spend on health care. And in 2011, Medicare spending reached close to $554 billion, which amounted to 21 percent of the total spent on U.S. health care in that year. Of that $554 billion, Medicare spent 28 percent, or about $170 billion, on patients¡¯ last six months of life. So what are the reasons of this high cost in EOL care and its possible solutions?Much spendings of Medicare on End-of-Life care for the terminally ill/chronically ill in the US has led health economics experts to assess the characteristics of the care. Decades of study shows that EOL care is usually supply-sensitive and poor in cost-effectiveness. The volume of care is sensitively depending on the supply of resources, rather than the severity of illness or preferences of patients. This means at the End-of-Life care, the medical resources are being overused. On the other hand, opposed to the common assumption, "The more care the better utility", the study shows that the outcome is very poor. Actually the patient preference and concerns are quite the opposite from what intense EOL care would bring about. This study analyzes the reasons for the supply-sensitiveness of EOL care. It can be resulted from the common misconception about the intense care and the outcome, physicians¡¯ mission for patients, lack of End-of-Life Care Decision which helps the patients choose their own preferred treatment intensity. It also could be resulted from physicians¡¯ fear of legal liabilities, and the management strategy since the hospitals are also seeking for financial benefits. This study suggests the possible solutions for over-treatment at the End-of-Life resulting from supply-sensitiveness. Solutions can be sought in two aspects, legal implementation and management strategy. In order to implement advance directive properly, active ethics education for physicians to change their attitude toward EOL care and more conversations about end-of-life care between physicians and patients is crucial, and incentive system for the physicians who actively have the conversations with patients will also help. Also, the general education towards the public is also important in the long run, and easy and official advance directive registry system - such as online registry - has to be built and utilized more widely. Alternative strategies in management are also needed. For example, the new strategic cost management and management education, such as cutting unnecessary costs and resetting values as medical providers have to be considered. In order to effectively resolve the problem in EOL care for the terminally ill/chronically ill and provide better experience to the patients, first of all, the misconception and the wrong conventional wisdom among doctors, patients, and the government have to be overcome. And then there should be improvements in systems and cultures of the EOL care.

Ű¿öµå

ÀÇ·á°æ, , ¸»±âÀÇ·á, ¿¬¸íÀÇ·á, ÀÇ·áÀÇ °ø±Þ¹Î°¨¼º, ºñ¿ëÈ¿À²¼º, »çÀüÀÇ·áÀÇÇâ¼­, ÀÇ·á°ü¸®Àü·«
Health Economics, End-of-Life Care, Life-Sustaining Care, Supply- Sensitive Care, Supply-Sensitiveness, Cost-Effectiveness, Advance Directive, Medical Management Strategy
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå